Canaccord Genuity Maintains Buy on Compass Therapeutics, Lowers Price Target to $7
Benzinga Newsdesk 6 months ago
NewsPrice TargetAnalyst Ratings
Canaccord Genuity analyst John Newman maintains Compass Therapeutics (NASDAQ:CMPX) with a Buy and lowers the price target from $13 to $7.
Canaccord Genuity analyst John Newman maintains Compass Therapeutics (NASDAQ:CMPX) with a Buy and lowers the price target from $13 to $7.